Texas OK’s $50 Million for Ibogaine Researchnews2025-06-14T19:18:02+00:00June 14th, 2025|The New York Times|
Qué es el lorazepam y cuáles son los riesgos de esta y otras benzodiacepinasnews2025-03-13T17:12:10+00:00March 13th, 2025|The New York Times|
What Is Lorazepam? The Drug From ‘The White Lotus’ Carries Real Risksnews2025-03-12T18:11:53+00:00March 12th, 2025|The New York Times|
FDA Approves Journavx Drug to Treat Pain Without Addiction Risknews2025-01-31T00:12:17+00:00January 31st, 2025|The New York Times|
What Kennedy’s Approach to Addiction Gets Wrongnews2024-12-22T12:40:41+00:00December 22nd, 2024|The New York Times|
El medicamento innovador para vencer la adicción: ¿Ozempic?news2024-11-06T10:40:06+00:00November 6th, 2024|The New York Times|
How The Opioid Crisis Turned Pharmacists Into Copsnews2024-10-28T09:00:58+00:00October 28th, 2024|The New York Times|
Jill Stein’s Third-Party Candidacynews2024-10-27T15:00:09+00:00October 27th, 2024|The New York Times|
Why We May Soon Use Ozempic to Treat Addictionnews2024-10-18T12:20:09+00:00October 18th, 2024|The New York Times|
Broken Again. A National Advocate for Drug Recovery Relapses.news2024-09-07T09:00:36+00:00September 7th, 2024|The New York Times|
